Oculus Innovative Sciences, Inc., a specialty pharmaceutical company, announced the receipt of several new US and foreign patents relating to its Microcyn Technology hypochlorous acid formulations. Specifically, the company has been granted a US patent, as well as a Canadian patent, for the use of the Oculus Microcyn Technology in the treatment of atopic dermatitis. In addition, two new patents in Mexico and Canada have recently been issued to Oculus relating to other hydrogel formulations and antimicrobial solutions.
Dr Bob Northey, Oculus senior vice president for research and development said: "We continue to focus on the expansion of our intellectual property portfolio. Our Microcyn-based products are now commercialized in more than forty countries worldwide. The evidence documenting Microcyn's efficacy and safety in the treatment of a broad spectrum of skin dermatoses is firmly aligned with our business strategy to increase Oculus' penetration of the dermatology market, the core focus of our marketing and sales efforts."
These newly issued patents expand Oculus' significant intellectual property portfolio (either owned or licensed to Oculus) that now includes 53 issued patents (12 in the United States and 41 foreign patents) as well as 70 pending patent applications (both US and foreign) directed to compositions, apparatuses, methods of manufacturing and therapeutic uses.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care.